Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Myeloid 2Other hematologic neoplasm 1

Conditions

Recurrence 2Primary Myelofibrosis 2Myeloproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

pembrolizumab 311Nivolumab 159Carboplatin 158Cisplatin 140Cyclophosphamide 135Paclitaxel 129Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 93Gemcitabine 88Dexamethasone 86Biopsy 81Ipilimumab 81Docetaxel 78Doxorubicin 77Rituximab 71Etoposide 69durvalumab 62Lenalidomide 61Radiation 61atezolizumab 60Prednisone 59Pemetrexed 58Taxes 58Bevacizumab 55fludarabine 54olaparib 53Vincristine 52Cytarabine 51Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × parsaclisib × 1 year × Clear all
NCT04809467 2026-02-04

topMIND

Incyte Corporation

Phase 1/2 Terminated
54 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Incyte Corporation

Phase 3 Terminated
252 enrolled 18 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Incyte Corporation

Phase 3 Terminated
177 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Incyte Corporation

Phase 2 Completed
60 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Incyte Corporation

Phase 2 Completed
110 enrolled 18 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡